

**Amendments to the Specification**

Please replace the existing paragraph on page 3, lines 13-25 of the specification with the following rewritten paragraph:

Now it has been found that these properties are owned by a peptide compound selected from the group ~~comprising~~ consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-Gly-R' (I) (SEQ ID NO: 1)

R-Gly-Pro-Gly- Val- Gly-Phe-Gly-Lys-Gly-Ile-Gly-Thr-Gly-Arg-Gly-Pro-Gly-Pro-Gly-Gln-R' (II) (SEQ ID NO: 2)

R-Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-Gly-R' (III) (SEQ ID NO: 3) and

~~R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-Val-Gly-Asn-R'~~ (IV) (SEQ ID NO:

~~4)~~

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Phe-Gly-His-Gly-Val-Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Please replace the existing paragraph from page 3, line 27 to page 4, line 11 of the specification with the following rewritten paragraph:

It is therefore a first object of the present invention to provide a peptide compound

Appln No. 09/926,234

Reply to the Office Action dated February 24, 2004

selected from the group comprising consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-  
Gly-R' (I) (SEQ ID NO: 1)

R-Gly-Pro-Gly- Val- Gly-Phe-Gly-Lys-Gly-Ile-Gly-Thr-Gly-Arg-Gly-Pro-Gly-Pro-Gly-  
Gln-R' (II) (SEQ ID NO: 2)

R-Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-  
Gly-R' (III) (SEQ ID NO: 3) and

~~R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-  
Val-Gly-Asn-R'~~ (IV) (SEQ ID NO:

~~4)~~

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Phe-Gly-His-Gly-Val-  
Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Please replace the existing paragraph on page 5, lines 7-21 of the specification with the following rewritten paragraph:

It is therefore a second object of the present invention to provide a pharmaceutical composition, which comprises a therapeutically effective dose of a peptide selected from the group comprising consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-  
Gly-R' (I) (SEQ ID NO: 1)

R-Gly-Pro-Gly- Val- Gly-Phe-Gly-Lys-Gly-Ile-Gly-Thr-Gly-Arg-Gly-Pro-Gly-Pro-Gly-

Appln No. 09/926,234  
Reply to the Office Action dated February 24, 2004

Gln-R' (II) (SEQ ID NO: 2)  
R-Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-  
Gly-R' (III) (SEQ ID NO: 3) and  
R-Gly-Ser-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Val-Gly-Asn-Gly-Gly-Phe-Gly-His-Gly-  
~~Val-Gly-Asn-R'~~ (IV) (SEQ ID NO:  
4)  
R-Gly-Ser-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Val-Gly-Asn-Gly-Phe-Gly-His-Gly-Val-  
Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R, R', the amino acid configurations have the above mentioned meanings, and at  
least a pharmaceutically acceptable inert ingredient.

Please replace the existing paragraph on page 5, line 22 to page 6, line 11 of the  
specification with the following rewritten paragraph:

It is still another object of this invention to provide a method of treating a patient  
suffering from Multiple Sclerosis, said method comprising administering to a patient in need  
thereof an effective amount of a peptide selected from the group ~~comprising~~ consisting of:

R-Asn-Gly-Val-Gly-His-Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-  
Gly-R' (I) (SEQ ID NO: 1)  
R-Gly-Pro-Gly-Val-Gly-Phe-Gly-Lys-Gly-Ile-Gly-Thr-Gly-Arg-Gly-Pro-Gly-Pro-Gly-  
Gln-R' (II) (SEQ ID NO: 2)  
R-Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-  
Gly-R' (III) (SEQ ID NO: 3) and  
~~R-Gly-Ser-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Val-Gly-Asn-Gly-Gly-Phe-Gly-His-Gly-~~

Appln No. 09/926,234  
Reply to the Office Action dated February 24, 2004

~~Val-Gly-Asn-R'~~

~~(IV) (SEQ ID NO:~~

~~4)~~

~~R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Phe-Gly-His-Gly-Val-~~  
~~Gly-Asn-R'~~ (IV) (SEQ ID NO: 4)

where R, R' and the amino acid configurations have the above mentioned meanings.

Please replace the existing paragraph on page 10, lines 17-22 of the specification with the following rewritten paragraph:

In the same way, peptides were also prepared:

Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-Gly  
(III) (SEQ ID NO: 3)

~~Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-Val-~~  
~~Gly-Asn~~ (IV) (SEQ ID NO: 4)

~~Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Phe-Gly-His-Gly-Val-Gly-~~  
~~Asn~~ (IV) (SEQ ID NO: 4)